Technology Transfer Office
Actualité - Partnership

Institut Curie & MSD France sign a strategic framework agreement to accelerate clinical research in oncology

Institut Curie & MSD France announce the signature of a strategic framework agreement for two years aimed at optimizing and strengthening their collaboration in the field of clinical oncology research.

Building on existing multi-pathology clinical research collaborations, Institut Curie and MSD France have signed a new framework agreement for a period of two years.  The collaboration aims to define and implement a scientific collaboration strategy between the two partners in the field of clinical, interventional and non-interventional research.

The objective of this agreement is to optimize the conduct of all MSD clinical studies conducted at Institut Curie. It will cover 21 ongoing or new studies in different types of cancers and therapeutic areas of interest (pediatrics, pulmonology, breast, head and neck, urology, etc.).

In order to increase this transverse approach to clinical research, the collaboration between Institut Curie and MSD will mainly be based on:

  • Optimizing the evaluation and validation process for clinical trials supported by MSD France;
  • Accelerated launch for MSD-supported trials;
  • Regular sharing of information on the progress of all MSD projects conducted at Institut Curie and improved management of ongoing trials.

This partnership fits perfectly with the partnership and innovative research strategy launched by the Institut Curie in 2017, as explains Amaury Martin, Head of Technology Transfer and Industrial Partnerships at Institut Curie & Carnot Curie Cancer:

Since the launch of the MC21 establishment project, Institut Curie has been implementing an ambitious strategy for the valorization of research and the development of partnerships with innovative companies in oncology. This partnership with MSD consolidates our efforts to develop effective clinical research and will provide access to innovative molecules for patients treated at Institut Curie. 

Each year, Institut Curie includes more than 2,000 patients in approximately 200 clinical studies open to inclusion, thus offering nearly 15% of its active patient file the opportunity to enter a study. Certified ISO:9001 2015 (certificate no. 2017/74557) for its clinical research activities, Institut Curie focuses on the quality of study execution in compliance with good practices and the safety of participating patients.

Our policy of continuous improvement and our dynamic creation of opportunities are assets at the service of our privileged partners.

emphasizes Véronique Gillon, PharmD, Operational Director of Research for the Hospital Complex at Institut Curie.